TY - JOUR AU - Masago, Katsuhiro AU - Horio, Yoshitsugu AU - Fujita, Shiro AU - Yatabe, Yasushi PY - 2019 TI - Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer JF - Translational Lung Cancer Research; Vol 8, Supplement 4 (December 31, 2019): Translational Lung Cancer Research Y2 - 2019 KW - N2 - Xu et al . performed a post-hoc analysis of a randomized phase III trial (ADJUVANT/CTONG1104) of adjuvant gefitinib therapy in the treatment of Chinese patients who had undergone complete resection for EGFR-mutant stage II-IIIA non-small cell lung cancer (NSCLC) to evaluate patterns of spatial-temporal treatment-failure (1,2). Two hundred twenty-two patients were randomized 1:1 to receive gefitinib or vinorelbine plus cisplatin (VP). Among them, 106 patients received gefitinib treatment, and 87 patients who received VP completed 4 cycles of chemotherapy. One hundred twenty-four patients experienced disease progression during a median follow-up period of 36.5 months. UR - https://tlcr.amegroups.org/article/view/31585